Five Fallen Biotech Stocks We're Watching for Rebounds

Edward Kim  |

Image source: Chokniti Khongchum / Pixabay

Biotech investors have generally been on the wrong end of the trade in 2022, with poor absolute performance and relative performance that lags the market.

The Nasdaq Biotechnology Index is off 19.2% year-to-date, compared to an 18.7% decline for the Nasdaq Composite and a 10.6% loss for the S&P 500 Index.

In an environment where the megacap technology stocks lead the market in both directions, we think investors who are willing to take the time to do a little research can find opportunities in biotech and life sciences, particularly at the smaller end of the market cap spectrum.

We highlight five today that we're watching for potential rebounds over the next 12 months:

 

Innate Pharma

Stocks To Watch in 5G Wireless Growth Wave

IPHA)

 

BioXcel TherapeuticsBTAI)

 

Editas MedicineEDIT)

 

AffimedAFMD)

 

GenfitGNFT)

 

Which companies are you following, biotech or otherwise? Let us know, and we promise to write about several of the submissions. Please email us at editor@equities.com.

Thank you.

_____

Source: Equities News

 

 

 

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility
Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market

Market Movers

Sponsored Financial Content